BMS Bolsters Pipeline with Two Billion-Dollar Deals

By Michelle Liu

Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)

Published: 17 Jun-2021

DOI: 10.3833/pdr.v2021.i6.2613     ISSN: 1756-7874

Section: Licensing



Bristol Myers Squibb has agreed to pay US$200 M upfront to access Agenus’ bispecific TIGIT antibody AGEN1777, which is currently in late preclinical development...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details